Prelude Therapeutics INC 8-K filings

NASDAQ

10 Apr 2024

PRLD

8-K: Prelude Therapeutics Announces CFO Departure and Appoints Interim Replacement

Prelude Therapeutics has announced the departure of its Chief Financial Officer, Laurent Chardonnet, and the appointment of its Chief Legal Officer, Bryant D. Lim, as interim CFO, effective April 8, 2024.

NASDAQ

15 Feb 2024

PRLD

Prelude Therapeutics INC

8-K: Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines 2024 Objectives

Prelude Therapeutics announced its full year 2023 financial results, highlighting progress in its clinical programs and outlining key objectives for 2024, including advancing its SMARCA2 degrader and CDK9 inhibitor programs.